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SUMMARY  
ORAI channels regulate Ca2+ signalling in multiple cell types and could be targeted in the 
treatment of PH. 
 
ABSTRACT  
Pulmonary hypertension is a complex and fatal disease which lacks treatments. Its 
pathophysiology involves pulmonary artery hyper-reactivity, endothelial dysfunction, wall 
remodelling, inflammation and thrombosis which could all depend on ORAI Ca2+ channels. 
We review the knowledge about ORAI channels in pulmonary artery and discuss the interest 
to target them in the treatment of pulmonary hypertension.  
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1. Pulmonary hypertension (PH) and ORAI channels: state of the art 
 
1.1 PH pathophysiology  
 
PH is defined by a sustained mean pulmonary artery (PA) SUHVVXUHPP+J at rest. It is a 
rare, progressive chronic disease. Over the time, elevated pulmonary artery pressure induces 
right ventricular hypertrophy followed by dilation leading to cardiac insufficiency and 
eventually, death. PH can originate from a heterogeneous spectrum of conditions that have 
been classified into five groups (21). PH from Group 1, also referred as ³3XOPRQDU\DUWHULDO
K\SHUWHQVLRQ 3$+´, develops in the absence of another cardiovascular condition. This 
includes idiopathic PAH (iPAH), heritable forms and PAH developed secondary to drug 
toxicity or infection. Group 1 contains the most severe forms of PH with development of 
plexiform lesions and angioproliferative occlusions. PH from Groups 2-5 are secondary to 
other cardio-respiratory diseases: Group 2: Pulmonary hypertension due to left heart disease, 
Group 3: Pulmonary hypertension due to lung diseases or hypoxia, Group 4: Chronic 
thromboembolic pulmonary hypertension, Group 5: PH due to unclear mechanisms or mixed 
aetiology. Although they have different origins and development, all forms of PH share 
common features that lead to elevation in PA pressure including PA wall remodelling, 
increased PA constriction and in situ thrombosis (13) resulting from complex cellular 
dysfunctions and altered intercellular crosstalk (48).  
 
Endothelial dysfunction is found in most types of PH (78). Pulmonary Artery Endothelial 
Cells (PAEC) and Pulmonary Micro-Vascular Endothelial Cells (PMVEC) produce less 
vasodilators (e.g. nitric oxide), more vasoconstrictors and factors that promote PASMC 
remodelling (e.g. endothelin-1) which overall increase the vascular tone (22). The 
endothelium becomes more permeable and pro-thrombotic, facilitating inflammation, cell 
migration and thrombus formation. In severe forms of PH, concentric proliferation of 
Endothelial Cells (EC) and endothelial-mesenchymal transition lead to vascular occlusion, 
probably due to complex mechanisms involving EC apoptosis followed by emergence of 
apoptotic resistant and hyperproliferative EC (48, 55, 59, 78).  
Media remodelling is also a common feature in PH. Proliferation, apoptosis resistance and 
migration of PASMC lead to an increase in media thickness and muscularization of distal 
arterioles which contribute to the elevation of PA pressure (13). 
Proliferation and differentiation of fibroblasts into myofibroblasts, together with extracellular 
matrix secretion contribute to the adventitial remodelling observed in animal models and 
human forms of PH (66).  
Inflammation in PH is characterised by immune cells infiltrate, comprising T- and B-
lymphocytes, macrophages, dendritic cells and mast cells which are found around vascular 
lesions in PAH patients and PH animal models. Circulating concentration of inflammatory 
cytokines is also elevated in patients with PAH and the presence of auto-antibodies has been 
detected in some cases of PAH (54).  
Abnormal platelet activation has been found in patients with Group 1 and Group 4 PH (34, 
80). Although it is not always clear whether platelet activation is a cause or a consequence of 
PH, it is likely to contribute to in situ thrombosis (34, 56, 79, 80).  
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All these cellular alterations are governed by multiple factors, notably hypoxia, inflammatory 
cytokines and growth factors such as Platelet Derived Growth Factor (PDGF) and Vascular 
Endothelial Growth Factor (VEGF) (48, 60).  
Non-specific therapeutic strategies include administration of oxygen, diuretics, anti- 
coagulants (16). Specific pharmacotherapies available for Group 1 PH target prostacyclin, 
endothelin-1 and nitric oxide pathways which primarily reduce PASMC contraction and 
vascular cell proliferation, with possible anti-inflammatory effect (12, 35). Although they 
have proved efficacy, many patients do not respond (35). Voltage-gated Ca2+ channel 
blockers also show limited benefits (42). Groups 2-5 PH lack specific therapies and molecules 
used with Group 1 patients show unclear to no effect (7, 79). The development of new drugs 
targeting alternative pathways is therefore necessary. 
1.2 Molecular identity and regulation of ORAI channels 
 
Calcium (Ca2+) is a key second messenger in a large variety of cellular processes. Variations 
in intracytoplasmic Ca2+, originating either from intracellular stores or extracellular space, 
control different cellular processes such as secretion, migration, contraction, gene expression 
including in PH (18, 32, 41). Among the different Ca2+ channels, the non-voltage-gated ORAI 
channels regulate extracellular Ca2+ entry in almost every cell type. The three ORAI proteins 
(ORAI1/2/3) are expressed at the plasma membrane and form the pore of Ca2+-selective 
channels. ORAI channels also depend on the two STromal Interaction Molecules (STIM1/2) 
expressed at the endo-/sarcoplasmic reticulum (ER/SR) membrane and, in the case of STIM1, 
at the plasma membrane. ORAI and STIM proteins form two types of Ca2+ channels, the 
store-operated Ca2+ Release Activated Ca2+ Channel (CRAC) and the receptor operated 
Arachidonic acid/Leukotriene Regulated Channel (ARC/LRC) (Figure 1).  
The CRAC channel mediates a sub-type of the cellular function named ³store-operated Ca2+ 
entry´ (SOCE). SOCE happens following activation of Gq/11-coupled receptors or tyrosine 
kinase receptors that activate Phospholipase C (PLC) which converts plasma membrane 
phospholipids into Inositol triphosphate (IP3) and Diacylglycerol (DAG). IP3 binding to its 
receptor (IP3R) allows passive depletion in ER/ES intraluminal Ca2+ which is sensed by STIM 
proteins and triggers their aggregation into puncta close to the plasma membrane. The 
subsequent interaction between STIM and ORAI proteins enables extracellular Ca2+
 
entry 
through ORAI proteins organized in hexamers at the plasma membrane. Experimental 
activation of SOCE is usually obtained by treating cells with the Sarcoendoplasmic Reticulum 
Ca2+ transport ATPase (SERCA) inhibitors Cyclopiazonic Acid (CPA) or Thapsigargin (TG), 
resulting in passive depletion in intraluminal Ca2+ (Figure 1). The vast majority of studies 
describe a CRAC channel formed of STIM1 and ORAI1 proteins. STIM2 contributes to 
SOCE with different sensitivity to store-depletion than STIM1 and probably regulates basal 
cytoplasmic Ca2+ concentration or SOCE under low agonist stimulation (71). ORAI2 can 
mediate SOCE but conflicting results exist regarding its role in enhancing or reducing SOCE 
(14, 72) (Figure 1). ORAI3 is also able to mediate SOCE but an ORAI3 dependent CRAC 
channel has only been described in a subset of breast cancer cells (45). Although the CRAC 
channel is considered as the main SOCE driver, SOCE can also be driven by Transient 
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Receptor Potential-Canonical (TRPC) channels, either in parallel or secondary to the CRAC 
channel activation (71). The TRPC channels are not discussed in this review. 
ARC/LRC channel activation is independent of Ca2+ store depletion but depends on 
Arachidonic Acid (AA) or its metabolite Leukotriene C4 (LTC4) (84). AA can be synthesised 
downstream of the PLC/DAG pathway or following Phospholipase A2 activation (PLA2) (71) 
(Figure 1). ARC/LRC channels have been described as a heteropentameric assembly of three 
ORAI1 and two ORAI3 proteins with STIM1 at the plasma membrane and at the ER 
membrane (24, 43, 84) (Figure 1). The role of STIM2 and ORAI2 in ARC/LRC channels has 
not been reported (71). 
 
Here we review the current knowledge about ORAI channels in cell types contributing to the 
development of PH and discuss the interest of targeting these channels as a new therapeutic 
strategy. 
 
2. ORAI channels in PA and PH 
 
2.1 EC proliferation, apoptosis and permeability 
 
ORAI1 and STIM1 are expressed in rat, mouse and human PMVEC (69, 76) and human 
PAEC (1). Both STIM1- and ORAI1-knockdown inhibit thrombin-induced SOCE in human 
PAEC (1). However, only STIM1-inhibition (by knockdown or expression of a dominant 
negative) but not ORAI1-inhibition reduces TG-induced SOCE in mouse and human PMVEC 
(69), suggesting that ORAI1 mediates SOCE in EC only in macro-vasculature. Strict 
comparison between lung vascular beds will be necessary to understand the role of ORAI1 
and STIM1 in PAEC and PMVEC.  
In mouse and human PMVEC, ORAI2 is not detectable and the expression of ORAI3 and 
STIM2 is very low; their function has not been investigated (69). 
There are indications that ORAI channels in PAEC and PMVEC play a role in stress and 
disease conditions but their exact function is unclear. Notably, basal intracellular Ca2+ and 
CPA-induced SOCE are increased in human PAEC cultured in chronic hypoxia (17) but they 
are decreased in PAEC freshly isolated from chronic hypoxic rats (51) possibly through a 
reduction in ORAI1/STIM1 interaction (82). Therefore, whether chronic hypoxia enhances or 
reduces Ca2+ signalling in PAEC and the role of ORAI channels will require further 
investigation.  
VEGF activates an ORAI1-dependent CRAC channel in Human Umbilical Vein EC 
(HUVEC), Saphenous Vein EC (SVEC) and Endothelial Progenitor Cells as well as an 
ORAI3-dependent ARC/LRC channel in HUVEC, SVEC, Cardiac Microvascular EC and 
Liver EC (36, 37). HUVEC migration, proliferation and tube formation are inhibited by 
ORAI1- and ORAI3-knockdown (1, 36, 37). VEGF signalling is important in PH: VEGF 
receptor inhibition associated with hypoxia triggers severe PH in animal models and high 
levels of VEGF and VEGF receptor are detected in lesions form patients with PAH, 
suggesting their contribution to pathogenic angioproliferation (75). The role of ORAI 
channels in VEGF dependent PH pathogenesis remains to be determined.  
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In rat PMVEC, ORAI1- and STIM1-knockdown reduce Bax and Caspase-3 expression and 
cell death in a model of endothelial dysfunction induced by lipopolysaccharide suggesting 
that ORAI1 and STIM1 promote apoptosis (76).  
Zhou et al reported that TG-induced endothelial permeability is more important in rat models 
of severe PAH than in models of mild PH and in controls. The mechanism was partially 
attributed to TRPC4 but the role of ORAI channels has not been investigated (85). Conflicting 
results have been obtained regarding the role of ORAI channels in vascular permeability. 
High-mobility group box 1 protein (HMGB1)-induced permeability is reduced by STIM1- 
and ORAI1- knockdown and non-specific CRAC blockers SKF96365 and 2-APB in HUVEC 
cell line EA.hy926 (86). However Stolwijk et al showed that thrombin- and histamine- 
induced permeability in human dermal microvascular endothelial cells depends on STIM1 but 
not on Ca2+ store release, ORAI1 expression or extracellular Ca2+ entry (67). Therefore, the 
role of ORAI channels in vascular permeability might vary depending on the vascular bed and 
the stimulus.  
Altogether, these data suggest that ORAI channels play a role in PAEC and PMVEC 
proliferation, apoptosis and permeability but a better comprehension of their function in the 
pulmonary vasculature is necessary to evaluate their interest as a drug target in PH. 
 
2.2 PASMC proliferation and migration 
 
ORAI1 and STIM1 expression has been detected in human, mouse and rat PASMC (10, 19, 
27, 46, 47, 63, 77). Their expression correlates with the proliferative phenotype of PASMC: 
treatment of proliferative rat PASMC with factors inducing differentiation into contractile 
phenotype (TGF-E and heparin) leads to lower expression of ORAI1 in the case of TGF-E and 
ORAI1and STIM1 in the case of heparin (19). CPA-induced SOCE is reduced by ORAI1- or 
STIM1-knockdown and increased by STIM1-overexpression in cultured PASMC (39, 47). 
Similarly, in rat aortic smooth muscle cells, ORAI1- and STIM1-expression is higher in 
proliferative cells than in freshly isolated cells. ORAI1- and STIM1-knockdown reduce TG-
induced SOCE and also proliferation and migration of proliferative aortic smooth muscle cells 
(53) raising the possibility of a role of ORAI and STIM1 in PASMC remodelling.  
Hypoxia regulates ORAI1 and STIM1 expression and function in PASMC. The expression of 
ORAI1 is enhanced in distal pulmonary artery of chronic normobaric hypoxic rat and mice 
(21 days, 10% O2) (77). This study reports no change in STIM1 expression, however STIM1 
expression is increased in distal pulmonary artery of chronic hypobaric hypoxic rats (21 days, 
380 mmHg) (28, 77). Although different cell types are present in the distal pulmonary artery, 
most in vitro studies show that chronic hypoxia enhances ORAI1 and STIM1 expression in rat 
and human PASMC (11, 27, 28, 62, 77) which leads to an increase in TG- or CPA-induced 
SOCE (11, 28, 77). The mechanisms by which hypoxia enhances ORAI1 and STIM1 proteins 
expression are not clear. The Hypoxia Induced Factor 1 alpha (HIFĮplays a role in PASMC 
remodelling in response to hypoxia (61) but does not seem to regulate ORA1 expression (77). 
However, chronic hypoxia-induced increase in ORAI1 and STIM1 expression might depend 
on the production of hydrogen peroxide (H2O2) (11). In addition to increasing ORAI1 and 
STIM1 protein expression, hypoxia can also activate ORAI channels as acute hypoxia was 
shown to induce a STIM1- and ORAI1-dependent SOCE (39, 46), possibly by increasing 
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ORAI1/STIM1 interaction through a H2O2 dependent mechanism (11). The role of ORAI1 
and STIM1 in hypoxia induced remodelling is poorly studied. Only one study shows that 
STIM1-knockdown inhibits hypoxia induced NFATc3 nuclear translocation and proliferation 
in rat PASMC (28).  
In human PASMC, PDGF increases CPA-induced SOCE and ORAI1 and STIM1 expression 
through the AKT/mTOR pathway (49). PDGF-induced SOCE, migration and proliferation are 
ORAI1- and STIM1-dependent in aortic (8) and airway smooth muscle cells (65, 68). 
Although not demonstrated in PASMC, these studies suggest that ORAI1 and STIM1 might 
mediate PDGF dependent remodelling in PH. 
 
ORAI2 and STIM2 are also expressed PASMC (10, 19, 27, 46, 47, 63, 77). Like STIM1 and 
ORAI1, STIM2 and ORAI2 expression is higher in proliferative (cultured) than in contractile 
(freshly isolated) rat PASMC and treatment of proliferative rat PASMC with factors inducing 
differentiation into contractile phenotype (TGF-E and heparin) leads to lower expression of 
ORAI2 and STIM2 (19). However, unlike ORAI1 and STIM1, ORAI2- and STIM2-
knockdown or STIM2-overexpression have little to no effect on CPA-induced SOCE in 
PASMC (10, 19, 27, 39, 46, 47, 63, 77). Similarly, ORAI2- and STIM2-knockdown has no 
effect on TG-induced SOCE, proliferation and migration in cultured aortic smooth muscle 
cells (53) and STIM2-knockdown has no effect on PDGF-induced SOCE and migration in 
airway smooth muscle cells (68), suggesting a minor role of ORAI2 and STIM2 in vascular 
smooth muscle cells.  
Nevertheless, the role of ORAI2 and STIM2 in PASMC might be important under stress and 
pathologic conditions. Like ORAI1 and STIM1, ORAI2 expression is enhanced in distal 
pulmonary artery of chronic hypoxic rat and mice (77) and STIM2 and ORAI2 expression is 
increased in PASMC cultured in chronic hypoxia (27, 62, 63, 77). ORAI2-knockdown 
reduces chronic hypoxia-induced increase in CPA-induced SOCE although the effect seems 
less important than ORAI1-knockdown (77). Contrary to ORAI1, hypoxia induced expression 
of ORAI2 depends on HIFĮindicating a distinct regulation mechanism (77).  
Nicotinamide phosphoribosyltransferase (NAMPT), a pro-inflammatory molecule which 
plasma concentration is increased in patients with PAH, induces the expression of ORAI2 and 
STIM2, but not ORAI1 and STIM1 in human PASMC. NAMPT-induced human PASMC 
proliferation is reduced by ORAI2- and STIM2-knockdown, indicating they play a role in 
response to inflammation (10).  
Similarly, the expression of ORAI2 and STIM2, but not STIM1, was found increased in 
PASMC from patients with iPAH as compared to PASMC from normal subjects (63, 64). 
Basal level of intracellular Ca2+, NFATc2 nuclear translocation, CREB-, STAT3-, AKT- 
phosphorylation, Bcl-2/Bax expression ratio and proliferation are enhanced in PASMC from 
patients with iPAH. Interestingly, these parameters can be reduced by STIM2-knockdown in 
PASMC from patients with iPAH and enhanced by STIM2-overexpression in control PASMC 
(63, 64). Although the role of ORAI1, ORAI2 and STIM1 in these mechanisms is not studied, 
the results suggest a pivotal role for STIM2 in Ca2+ regulation, proliferation and anti-
apoptotic phenotype of PASMC in iPAH.  
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Finally, ORAI3 is expressed in rat PASMC (19, 77), its expression correlates with PASMC 
proliferation (19) but is not modified by chronic hypoxia (11, 77). Globally the role of ORAI3 
in PASMC has not been studied. Interestingly, in rat PASMC, serotonin activates a store-
independent Ca2+ entry which depends on AA synthesis via the PLC/DAG/DAG-lipase 
pathway (15, 25). This signalling pathway seems of particular importance in serotonin 
induced Ca2+ signalling and contraction in chronic hypoxia (57) and could regulate the 
serotonin-dependent remodelling in PH (40). Part of the Ca2+ entry might depend on AA 
metabolism via the cytochrome P450 epoxygenase pathway leading to TRPV4 activation (15) 
but whether serotonin also activates an ORAI and STIM dependent ARC/LRC type channel is 
to be determined. An ARC/LRC type channel, activated by LTC4, has been described in rat 
aortic and carotid artery smooth muscle cells (24, 83). ORAI3 expression and LTC4-induced 
currents are increased in smooth muscle cells from rat carotid artery media and neointima 
after balloon injury (24) and ORAI3-silencing reduces neointima formation (24), showing a 
role of the ARC/LRC channel in smooth muscle cell remodelling. 
In total, there are multiple indications that ORAI channels regulate PASMC remodelling 
which suggest a possible benefit of inhibiting these channels in the treatment of PH. 
 
2.3 Fibroblasts 
 
The role of ORAI channels in vascular fibroblasts has not been studied. However, TG-
induced SOCE is massively reduced in Mouse Embryonic Fibroblasts (MEF) from STIM1- or 
ORAI-knockout mice and in skin fibroblast from patients carrying a mutation that abolishes 
STIM1 or ORAI1 expression (26, 33, 38, 50, 52). In all cases of ORAI1 or STIM1 deficiency, 
SOCE can be rescued by transient expression of the wild-type protein showing, the important 
role of ORAI1 and STIM1 for SOCE in fibroblasts. TG-induced SOCE is also reduced in 
MEF from STIM2-knocknout mice but the effect is less important than STIM1- or ORAI1-
knockout (26, 50). As far as we know, there are no data available about ORAI2 and ORAI3 in 
fibroblasts. Interestingly, pharmacological inhibition of the CRAC channel reduces 
extracellular matrix proteins secretion in cardiac fibroblast (58, 81), suggesting a role in 
fibrosis.  
ORAI channels in fibroblasts seem to regulate SOCE and fibrosis but their expression and 
function in PA fibroblasts still has to be studied. 
 
2.4 Immune cells in inflammation and auto-immunity 
 
There are currently no data about the role of ORAI channels in immune cells in the 
pathogenesis of PH. ORAI channels have a complex roles in the immune system as they both 
allow pro-inflammatory cytokine secretion and are necessary in regulatory T cells (Treg) to 
prevent auto-immunity (20). Nevertheless, moderate inhibition of the CRAC channel by drug 
administration could at the same time limit inflammation, preserve immune response to 
infection and preserve Treg function (20). Interestingly, oral administration of the CRAC 
channel blocker AMG1 prevents inflammation in experimental encephalomyelitis (EAE). In 
this mouse model of autoimmune disease of the central nervous system, inflammation is 
mediated by autoreactive Th1 and Th17 cells and promoted by defective Treg cells (31). 
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AMG1 treatment reduces pro-inflammatory cytokine secretion by Th1 and Th17, without 
affecting immuno-suppressive properties of Treg (31), indicating a potential way to reduce 
Th1/Th17 dependant inflammation in PH (33, 54). 
 
2.5 Platelet activation and thrombosis 
 
Human and murine platelets express ORAI1 and STIM1 (6). Platelets from STIM1-knockout 
mice, ORAI1-knockout mice or mice expressing the dominant negative ORAI1-R93W have 
reduced TG-induced SOCE, SOCE induced by pro-coagulant factors thrombin and Collagen 
related Peptide (CRP), and phosphatidylserine surface exposure (a key step in the coagulation 
process) (2, 4, 9, 23, 74). Despite these functional alterations, haemostasis seems to be 
moderately altered in mice with STIM1-knockout haematopoietic lineage and unaltered in 
mice with ORAI1-knockout haematopoietic lineage (2, 9, 74) suggesting a limited role of 
ORAI channels under physiological conditions. However, mice with ORAI1- or STIM1-
knockout platelets are protected against different models of thrombus formation (2, 9, 74). 
Notably, mice with ORAI1-knockout hematopoietic lineage are protected against a model of 
lethal pulmonary thromboembolism (9). van Kruchten et al showed that SOCE and in vitro 
thrombus formation induced by a combination of convulxin and thrombin (two platelet 
activators) are reduced in human platelets treated with different CRAC channel inhibitors, 
including the CRAC channel specific inhibitors Synta66 and GSK-7975A. The same study 
showed that treatment of mice with 2-APB reduced brain infarct in a model of ischemic stroke 
(73). Although 2-APB is not specific to the CRAC channel and investigation in PH is 
necessary, this study suggests that pharmacological inhibition of the CRAC channel could be 
used to limit thrombosis. 
Human and murine platelets also express ORAI2, ORAI3 and STIM2 (6). The role of ORAI2 
in platelets has not been studied. STIM2 seems of minor importance since CRP-induced Ca2+ 
signal and in vitro thrombus formation is unaltered in platelets from STIM2-knockout mice 
(23). AA seems to increase ORAI1/ORAI3 interaction in human platelets, suggesting the 
existence of an ARC/LRC type channel (5). The exact role of ORAI2, ORAI3 and STIM2 in 
platelets is therefore to be determined. 
 
2.6 Cardiac remodelling 
 
This review focuses on pulmonary artery but ORAI channels are also expressed in the heart 
and might contribute to right ventricular failure in PH. ORAI1 and STIM1 are expressed in 
cardiomyocytes where they have been shown to mediate cardiac hypertrophy and dilation (for 
review, see (3)). Interestingly, a recent study indicates a role of ORAI1 and STIM1 in right 
ventricular remodelling in a monocrotaline rat model of PH (30). ORAI1 and STIM1 are also 
expressed in cardiac fibroblasts and might contribute to cardiac fibrosis (58, 81). 
 
3. Clinical significance of ORAI channels and perspectives for PH 
 
Data presented in this review suggest that ORAI channels have a limited role under normal 
physiological conditions but might be important in PA remodelling, inflammation and 
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thrombosis in PH (Figure 2). Importantly, the potential role of ORAI channels in 
PDGF,VEGF and serotonin signalling, cytokine secretion and fibrosis might allow to target 
these therapeutically relevant but unexploited pathways (29). It is tempting to assume that 
inhibition of ORAI channels will have multiple beneficial effects but extensive study of their 
role in PA function and PH pathogenesis is necessary. In particular, STIM2, ORAI2 and 
ORAI3 are usually neglected but could have important role in the pathophysiology. 
There is currently no molecule targeting ORAI channels available for medical use. However 
the CRAC channel inhibitor CM4620 developed by Calcimedica has been approved for 
clinical trial in the treatment of acute pancreatitis and intervention on ORAI channels has 
been suggested to treat inflammation, cancer or cardiovascular diseases (20, 44, 70) showing 
a growing interest of these channels for drug development. Therefore the study of ORAI 
channels in PH should be strongly encouraged.       
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FIGURE LEGENDS 
 
FIGURE 1: Activation mechanisms of ORAI channels 
On the left hand side: the CRAC channel. Binding of a ligand (L1) to its receptor (R1) 
activates the PLC which synthesizes IP3 and DAG. IP3 binds to the IP3R at the ER\ES 
membrane, allowing Ca2+ release. The reduction in intraluminal Ca2+ concentration triggers 
STIM1 or STIM2 aggregation and their interaction with ORAI1 or ORAI2 (O1 or O2), 
enabling Ca2+ entry. The CRAC channel can also be activated by treatment with the SERCA 
pump inhibitors CPA or TG. On the right hand side: the ARC/LRC channel. AA is 
synthesised either downstream of DAG synthesis by the PLC or after binding of a ligand (L2) 
to its receptor (R2) coupled to the PLA2. The ARC/LRC channel can be activated either by 
AA itself or by its metabolite LTC4. The ARC/LRC channel depends on ORAI1 (O1), 
ORAI3 (O3) and STIM1 at ER\ES membrane or at the plasma membrane. 
 
FIGURE 2: Functions regulated by ORAI channels in the pulmonary artery in PH 
Functions regulated by ORAI channels are indicated for each cell type. Functions are in bold 
when clearly demonstrated in PA, in italic when extrapolated from other tissues or diseases 
and with a question mark when unclear.  
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